Literature DB >> 15288614

Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine.

Simon A Zanati1, Stephen A Locarnini, John P Dowling, Peter W Angus, Francis J Dudley, Stuart K Roberts.   

Abstract

Fibrosing cholestatic hepatitis (FCH) is a severe variant of hepatitis B infection that has until recently been described almost exclusively in the setting of organ transplantation and HIV infection. This case report describes a patient with pre-surface (pre-S) mutant hepatitis B virus (HBV) infection who developed a fatal form of FCH after high dose prednisolone for mixed connective tissue disease (MCTD). The role of corticosteroids and pre-S viral mutation in the pathogenesis of the disease is discussed, and the importance of early diagnosis is emphasised. This report alerts the physician to the need for close monitoring of LFTs and HBV DNA of hepatitis B carriers during immunosuppressive therapy regardless of the indication. As in the transplantation setting, viral DNA levels should be kept to undetectable if viral replication or recurrence is to be prevented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15288614     DOI: 10.1016/j.jcv.2004.02.013

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  8 in total

Review 1.  Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

Authors:  Pilar López-Serrano; Elsa de la Fuente Briongos; Elisa Carrera Alonso; Jose Lázaro Pérez-Calle; Conrado Fernández Rodríguez
Journal:  World J Hepatol       Date:  2015-03-27

2.  Clinicopathological features of hepatitis B virus recurrence after liver transplantation: eleven-year experience.

Authors:  Donghong Zhang; Zuoyi Jiao; Jixiang Han; Hongtai Cao
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus.

Authors:  Philip Meuleman; Louis Libbrecht; Stefan Wieland; Rita De Vos; Nagy Habib; Anna Kramvis; Tania Roskams; Geert Leroux-Roels
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 4.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 5.  Hepatitis B virus large surface protein: function and fame.

Authors:  Yuri Churin; Martin Roderfeld; Elke Roeb
Journal:  Hepatobiliary Surg Nutr       Date:  2015-02       Impact factor: 7.293

6.  Fibrosing cholestatic hepatitis with hepatitis C virus treated by double filtration plasmapheresis and interferon plus ribavirin after liver transplantation.

Authors:  Teruki Miyake; Kojiro Michitaka; Yoshio Tokumoto; Shinya Furukawa; Teruhisa Ueda; Yoshiko Soga; Masanori Abe; Bunzo Matsuura; Taro Nakamura; Taiji Tohyama; Nobuaki Kobayashi; Yoichi Hiasa; Morikazu Onji
Journal:  Clin J Gastroenterol       Date:  2009-01-10

7.  Management of HBV infection during immunosuppressive treatment.

Authors:  Alfredo Marzano
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-22       Impact factor: 2.576

Review 8.  Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review.

Authors:  Dandan Xuan; Yiqi Yu; Linyun Shao; Jiali Wang; Wenhong Zhang; Hejian Zou
Journal:  Clin Rheumatol       Date:  2013-12-11       Impact factor: 2.980

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.